Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Depreciation & Amortization (CF) (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $360000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Depreciation & Amortization (CF) fell 4.76% year-over-year to $360000.0, compared with a TTM value of $360000.0 through Mar 2024, down 76.74%, and an annual FY2023 reading of $744000.0, down 52.52% over the prior year.
  • Depreciation & Amortization (CF) was $360000.0 for Q2 2023 at Spyre Therapeutics, down from $384000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $412000.0 in Q3 2021 and bottomed at $100000.0 in Q1 2019.
  • Average Depreciation & Amortization (CF) over 5 years is $294500.0, with a median of $364500.0 recorded in 2020.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 248.11% in 2020, then dropped 6.33% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $106000.0 in 2019, then surged by 248.11% to $369000.0 in 2020, then rose by 11.38% to $411000.0 in 2021, then decreased by 6.33% to $385000.0 in 2022, then decreased by 6.49% to $360000.0 in 2023.
  • Business Quant data shows Depreciation & Amortization (CF) for SYRE at $360000.0 in Q2 2023, $384000.0 in Q1 2023, and $385000.0 in Q4 2022.